oxidopamine has been researched along with Anhedonia in 5 studies
Oxidopamine: A neurotransmitter analogue that depletes noradrenergic stores in nerve endings and induces a reduction of dopamine levels in the brain. Its mechanism of action is related to the production of cytolytic free-radicals.
oxidopamine : A benzenetriol that is phenethylamine in which the hydrogens at positions 2, 4, and 5 on the phenyl ring are replaced by hydroxy groups. It occurs naturally in human urine, but is also produced as a metabolite of the drug DOPA (used for the treatment of Parkinson's disease).
Anhedonia: Inability to experience pleasure due to impairment or dysfunction of normal psychological and neurobiological mechanisms. It is a symptom of many PSYCHOTIC DISORDERS (e.g., DEPRESSIVE DISORDER, MAJOR; and SCHIZOPHRENIA).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Parkinson's disease is a chronic neurodegenerative disorder characterized by cardinal motor features, such as bradykinesia, but also vocal deficits (e." | 5.48 | Effects of ketamine on vocal impairment, gait changes, and anhedonia induced by bilateral 6-OHDA infusion into the substantia nigra pars compacta in rats: Therapeutic implications for Parkinson's disease. ( Andreatini, R; Bruginski, E; Campos, FR; de Almeida Soares Hocayen, P; Kanazawa, LKS; Miyoshi, E; Schwarting, RKW; Stern, CAJ; Vecchia, DD; Vital, MABF; Wendler, E; Wöhr, M, 2018) |
| "Parkinson's disease is a neurodegenerative disorder partly caused by the loss of the dopamine neurons of the nigrostriatal pathway." | 1.56 | Ablation of the tail of the ventral tegmental area compensates symptoms in an experimental model of Parkinson's disease. ( Barrot, M; Bezard, E; Bido, S; Dovero, S; Faivre, F; Joshi, A; Sánchez-Catalán, MJ, 2020) |
| "Parkinson's disease is a chronic neurodegenerative disorder characterized by cardinal motor features, such as bradykinesia, but also vocal deficits (e." | 1.48 | Effects of ketamine on vocal impairment, gait changes, and anhedonia induced by bilateral 6-OHDA infusion into the substantia nigra pars compacta in rats: Therapeutic implications for Parkinson's disease. ( Andreatini, R; Bruginski, E; Campos, FR; de Almeida Soares Hocayen, P; Kanazawa, LKS; Miyoshi, E; Schwarting, RKW; Stern, CAJ; Vecchia, DD; Vital, MABF; Wendler, E; Wöhr, M, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Faivre, F | 1 |
| Sánchez-Catalán, MJ | 1 |
| Dovero, S | 1 |
| Bido, S | 1 |
| Joshi, A | 1 |
| Bezard, E | 1 |
| Barrot, M | 1 |
| Vecchia, DD | 1 |
| Kanazawa, LKS | 1 |
| Wendler, E | 1 |
| de Almeida Soares Hocayen, P | 1 |
| Bruginski, E | 1 |
| Campos, FR | 1 |
| Stern, CAJ | 1 |
| Vital, MABF | 1 |
| Miyoshi, E | 1 |
| Wöhr, M | 1 |
| Schwarting, RKW | 1 |
| Andreatini, R | 2 |
| Marques, NF | 1 |
| Binder, LB | 1 |
| Roversi, K | 1 |
| Sampaio, TB | 1 |
| Constantino, LC | 1 |
| Prediger, RD | 2 |
| Tasca, CI | 1 |
| Santiago, RM | 1 |
| Tonin, FS | 1 |
| Barbiero, J | 1 |
| Zaminelli, T | 1 |
| Boschen, SL | 1 |
| Da Cunha, C | 1 |
| Lima, MM | 1 |
| Vital, MA | 1 |
| Matheus, FC | 1 |
| Rial, D | 1 |
| Real, JI | 1 |
| Lemos, C | 1 |
| Takahashi, RN | 1 |
| Bertoglio, LJ | 1 |
| Cunha, RA | 1 |
5 other studies available for oxidopamine and Anhedonia
| Article | Year |
|---|---|
Ablation of the tail of the ventral tegmental area compensates symptoms in an experimental model of Parkinson's disease.
Topics: Anhedonia; Animals; Dopamine; Dopaminergic Neurons; Male; Models, Theoretical; Neural Pathways; Oxid | 2020 |
Effects of ketamine on vocal impairment, gait changes, and anhedonia induced by bilateral 6-OHDA infusion into the substantia nigra pars compacta in rats: Therapeutic implications for Parkinson's disease.
Topics: Anhedonia; Animals; Depression; Disease Models, Animal; Gait; Imipramine; Ketamine; Male; Nerve Dege | 2018 |
Guanosine prevents depressive-like behaviors in rats following bilateral dorsolateral striatum lesion induced by 6-hydroxydopamine.
Topics: Anhedonia; Animals; Brain; Corpus Striatum; Depression; Disease Models, Animal; Dopamine; Guanosine; | 2019 |
The nonsteroidal antiinflammatory drug piroxicam reverses the onset of depressive-like behavior in 6-OHDA animal model of Parkinson's disease.
Topics: Anhedonia; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents; Depressive Disor | 2015 |
Temporal Dissociation of Striatum and Prefrontal Cortex Uncouples Anhedonia and Defense Behaviors Relevant to Depression in 6-OHDA-Lesioned Rats.
Topics: Anhedonia; Animals; Behavior, Animal; Corpus Striatum; Depression; Dopamine Plasma Membrane Transpor | 2016 |